# Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/continuous-versus-1-year-fixed-duration-nivolumab-in-previously-treated-advanced/

## Facts

| Field | Value |
| --- | --- |
| Author Names | David Waterhouse,Edward B. Garon,Jason C. Chandler,Michael McCleod,Maen Hussein,Robert M. Jotte,Leora Horn,Davey B. Daniel,George P. Keogh,Ben Creelan,Lawrence H. Einhorn,Justin Baker,Samer S. Kasbari,Petros Nikolinakos,Sunil Babu,Félix Couture,Natasha B. Leighl,Craig H. Reynolds,George R. Blumenschein,Vijay Gunuganti,Ang Li,Nivedita Aanur,David R. Spigel |
| Citations | 241 |
| DOI | 10.1200/jco.20.00131 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.00131 |
| OpenAlex ID | https://openalex.org/W3085379405 |
| PMID | 32910710 |
| Type | article |
| Year | 2020 |

## Paper authors

- [George R. Blumenschein](https://scholariq.org/researchers/george-r-blumenschein/)
- [Edward B. Garon](https://scholariq.org/researchers/edward-b-garon/)
- [Ben Creelan](https://scholariq.org/researchers/ben-creelan/)
- [David R. Spigel](https://scholariq.org/researchers/david-r-spigel/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.